News & analysis on the clinical development and manufacture of large molecule drugs
News from Patheon, Wolfe Laboratories, and Premier Research – People on the move
By Natalie Morrison
- Last updated on
Wolfe Laboratories has named Dave Casebier as its new VP of pharmaceutical sciences.
Casebier joins the early biopharma development service provider from Tokai Pharmaceuticals, where he was senior VP for pharmaceutical sciences.
In his new role he will take charge of the firm’s research and development (R&D) strategy, with special focus on its proprietary analytical and formulation technology platforms.
Janet Wolfe, the company’s founder and president, said Casebier’s appointment is key to Wolfe’s expansion in the areas of complex small molecule dosage forms, biologics, biosimilars, and targeted therapeutics.
Former GlaxoSmithKline marketing chief Mark Vince has become the European director for MedErgy.
Vince’s career spans a number of senior clinical development roles with Ciba-Geigy, as well as GSK, where he established the medical marketing function.
He will now lead the management of existing clients for the science and healthcare marketing agency, as well as the the drive for new customers in Europe.
Julia Ralston, CEO of MedErgy, said his experience will be a “good fit with our culture”.
Horizon Discovery (Horizon) has appointed Eric Rhodes as chief technical officer for gene targeting.
The firm, which provides R&D services and cell lines to the pharma industry, says Rhodes will be its primary expert in human and mammalian gene targeting methods, and will have a hand in marketing its technology.
Prior to joining Horizon, he was business development director for Sigma-Aldrich.
Of his new role, he said: “I’m excited to join the team and look forward to helping to expand upon the range of markets and applications which the company will be addressing over the years ahead.”
Matt Grace has become the new director of Myoderm.
He comes to the company, which specialises in sourcing commercial drugs for clinical trials, from AstraZeneca, where he was an R&D sourcing manager.
Mike Cohen, MD at Myoderm, said: “Matt's experience at AstraZeneca UK and his insights about the EU market will help Myoderm to do an even better job of providing the optimal sourcing solution for each of our clients.”
Antonella Mancuso has been promoted as Patheon's president of global commercial operations and chief manufacturing officer.
Once the senior VP and MD of European operations for the firm, Mancuso will now oversee the firm’s global commercial manufacturing.
She first joined the firm in Mancuso 2001, when she was production manager of the facility in Monza, Italy.
Jim Mullen, Patheon's CEO, said he was keen to see the company’s manufacturing services united under Mancuso’s leadership.
Premier Research has drafted in Etienne Drouet as executive director of oncology in Europe.
Drouet will head teams in charge of operations, strategic planning and corporate development of the firm’s oncology business – for which it has set a growth strategy in place.
Before Premier Research, he held leadership positions at several organisations including Sanofi Aventis, Icon and Breast Cancer International Research Group.